Trial Profile
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2015
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 19 Nov 2015 New trial record